Everest Medicines Limited
HKSE: 1952.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yongqing Luo
- Employees
- 665
- Headquarters
- Shanghai, China
- IPO year
- 2020
- Market cap
- HK$11.5B
- Website
- https://www.everestmedicines.com
Loading 1952…
Loading profile data…Frequently asked questions about 1952
What does Everest Medicines Limited (1952.HK) do?
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, c...
Where does 1952.HK trade?
Everest Medicines Limited (1952.HK) trades on the Hong Kong Stock Exchange.
What sector is 1952.HK in?
Everest Medicines Limited (1952.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Everest Medicines Limited?
Yongqing Luo is the chief executive officer of Everest Medicines Limited (1952.HK).
Where is Everest Medicines Limited headquartered?
Everest Medicines Limited is headquartered in China.
Does 1952.HK pay a dividend?
Everest Medicines Limited (1952.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 1952.HK go public?
Everest Medicines Limited (1952.HK) completed its initial public offering in 2020.